saccharomyces boulardii and Reduced Headache

Time to effect

Median: 2 weeks · IQR 2 weeks–2 weeks · Range 2 weeks–2 weeks — Reported in 1 of 1 study

Safety in these studies

abdominal painIncreased riskOR=3.21
In Group S, the chance of developing symptoms of ... abdominal pain (OR=3.21) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillu
anxietyIncreased riskOR=3.58
In Group S, the chance of developing symptoms of ... anxiety (OR=3.58) was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillu
diarrheaIncreased riskOR=3.01
In Group S, the chance of developing symptoms of ... diarrhea (OR=3.01) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillu
headacheIncreased riskOR=10.51
In Group S, the chance of developing symptoms of ... headache (OR=10.51) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillu
nauseaIncreased riskOR=2.74
In Group S, the chance of developing symptoms of nausea (OR=2.74) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillu

1 of 1 paper

Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.